These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36393977)

  • 1. CES1 and SLC6A2 Genetic Variants As Predictors of Response To Methylphenidate in Autism Spectrum Disorders.
    Hernandez MH; Bote V; Serra-LLovich A; Cendros M; Salazar J; Mestres C; Guijarro S; Alvarez A; Lamborena C; Mendez I; Sanchez B; Hervas A; Arranz MJ
    Pharmgenomics Pers Med; 2022; 15():951-957. PubMed ID: 36393977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylphenidate side effect profile is influenced by genetic variation in the attention-deficit/hyperactivity disorder-associated CES1 gene.
    Johnson KA; Barry E; Lambert D; Fitzgerald M; McNicholas F; Kirley A; Gill M; Bellgrove MA; Hawi Z
    J Child Adolesc Psychopharmacol; 2013 Dec; 23(10):655-64. PubMed ID: 24350812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.
    Cho SC; Kim BN; Cummins TD; Kim JW; Bellgrove MA
    J Psychopharmacol; 2012 Mar; 26(3):380-9. PubMed ID: 21628343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients.
    Angyal N; Horvath EZ; Tarnok Z; Richman MJ; Bognar E; Lakatos K; Sasvari-Szekely M; Nemoda Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):122-128. PubMed ID: 29374517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder.
    Kim BN; Kim JW; Cummins TD; Bellgrove MA; Hawi Z; Hong SB; Yang YH; Kim HJ; Shin MS; Cho SC; Kim JH; Son JW; Shin YM; Chung US; Han DH
    J Clin Psychopharmacol; 2013 Jun; 33(3):356-62. PubMed ID: 23609393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible association of norepinephrine transporter -3081(A/T) polymorphism with methylphenidate response in attention deficit hyperactivity disorder.
    Kim BN; Kim JW; Hong SB; Cho SC; Shin MS; Yoo HJ
    Behav Brain Funct; 2010 Oct; 6():57. PubMed ID: 20929549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASD with ADHD vs. ASD and ADHD alone: a study of the QbTest performance and single-dose methylphenidate responding in children and adolescents.
    Stevanovic D; Wentz E; Nasic S; Knez R
    BMC Psychiatry; 2022 Apr; 22(1):282. PubMed ID: 35448977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylphenidate in Autism Spectrum Disorder: A Long-Term Follow up Naturalistic Study.
    Ventura P; de Giambattista C; Spagnoletta L; Trerotoli P; Cavone M; Di Gioia A; Margari L
    J Clin Med; 2020 Aug; 9(8):. PubMed ID: 32784735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD.
    Nemoda Z; Angyal N; Tarnok Z; Gadoros J; Sasvari-Szekely M
    Neuropharmacology; 2009 Dec; 57(7-8):731-3. PubMed ID: 19733552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylphenidate Use for Emotional Dysregulation in Children and Adolescents with ADHD and ADHD and ASD: A Naturalistic Study.
    Ventura P; de Giambattista C; Trerotoli P; Cavone M; Di Gioia A; Margari L
    J Clin Med; 2022 May; 11(10):. PubMed ID: 35629047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylphenidate for children and adolescents with autism spectrum disorder.
    Sturman N; Deckx L; van Driel ML
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011144. PubMed ID: 29159857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of
    Śmiarowska M; Brzuchalski B; Grzywacz E; Malinowski D; Machoy-Mokrzyńska A; Pierzchlińska A; Białecka M
    Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Extended-Release Methylphenidate Treatment on Cognitive Task Performance in Children with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
    Pearson DA; Santos CW; Aman MG; Arnold LE; Lane DM; Loveland KA; Mansour R; Ward AR; Casat CD; Jerger S; Schachar RJ; Bukstein OG; Cleveland LA
    J Child Adolesc Psychopharmacol; 2020 Sep; 30(7):414-426. PubMed ID: 32644833
    [No Abstract]   [Full Text] [Related]  

  • 15. Processing speed as a marker to stimulant effect in clinical sample of children with high functioning autism spectrum disorder.
    Peled J; Cassuto H; Berger I
    Nord J Psychiatry; 2020 Apr; 74(3):163-167. PubMed ID: 31686565
    [No Abstract]   [Full Text] [Related]  

  • 16. Associations between
    Brown JT; Beery N; Taran A; Stevens T; Henzler C; Badalamenti J; Regal R; McCarty CA
    Front Pediatr; 2022; 10():958622. PubMed ID: 36741090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms.
    Pearson DA; Santos CW; Aman MG; Arnold LE; Casat CD; Mansour R; Lane DM; Loveland KA; Bukstein OG; Jerger SW; Factor P; Vanwoerden S; Perez E; Cleveland LA
    J Child Adolesc Psychopharmacol; 2013 Jun; 23(5):337-51. PubMed ID: 23782128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct Methylphenidate-Evoked Response Measured Using Functional Near-Infrared Spectroscopy During Go/No-Go Task as a Supporting Differential Diagnostic Tool Between Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder Comorbid Children.
    Sutoko S; Monden Y; Tokuda T; Ikeda T; Nagashima M; Kiguchi M; Maki A; Yamagata T; Dan I
    Front Hum Neurosci; 2019; 13():7. PubMed ID: 30800062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-Response Effects of Long-Acting Liquid Methylphenidate in Children with Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study.
    Kim SJ; Shonka S; French WP; Strickland J; Miller L; Stein MA
    J Autism Dev Disord; 2017 Aug; 47(8):2307-2313. PubMed ID: 28474229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.
    Soutullo C; Banaschewski T; Lecendreux M; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Bloomfield R; Squires LA; Coghill DR
    CNS Drugs; 2013 Sep; 27(9):743-51. PubMed ID: 23801529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.